Related Experiment Videos

Zinc supplementation and TNF-α levels in vaccinated cardiac patients

S Songül Yalçın1, Defne Engür-Karasimav, Dursun Alehan

  • 1Unit of Social Pediatrics, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey. siyalcin@hacettepe.edu.tr

Insights

Zinc supplementation may reduce adverse reactions to influenza vaccines in children with heart conditions. It also helped lower serum tumor necrosis factor-alpha (TNF-α) levels, indicating a potential immune benefit.

Area of Science:

  • Immunology
  • Pediatric Cardiology
  • Nutritional Science

Background:

  • Children with congenital or acquired heart disease may have altered immune responses.
  • Influenza vaccination is crucial for this vulnerable population.
  • Zinc deficiency can impact immune function.

Purpose of the Study:

  • To evaluate the effect of zinc supplementation on serum tumor necrosis factor-alpha (TNF-α) levels in pediatric cardiac patients receiving an influenza vaccine.
  • To assess vaccine-associated adverse events and upper respiratory tract infection (URTI) rates.

Main Methods:

  • A randomized controlled trial involving children aged 9-18 with heart disease.
  • Participants received either zinc supplementation plus influenza vaccine (ZV group) or influenza vaccine alone (V group).
  • Serum zinc, TNF-α levels, and antibody titers were measured; adverse events and URTI incidence were recorded.

Main Results:

  • Congenital heart disease patients had lower baseline serum zinc levels compared to acquired heart disease patients.
  • Serum TNF-α levels significantly decreased in the ZV group post-vaccination.
  • Malaise as a vaccine side effect was significantly lower in the ZV group.
  • URTI incidence decreased significantly after vaccination in both groups.

Conclusions:

  • Zinc supplementation appears beneficial in mitigating malaise associated with influenza vaccination in children with heart disease.
  • Zinc supplementation may help reduce serum TNF-α levels following influenza vaccination in this population.
  • Further research into zinc's role in pediatric cardiac patient immunity is warranted.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...